PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
News|Articles|July 16, 2013
Penn Pharma Invests in Manufacturing Capacity
Author(s)Pharmaceutical Technology Editors
Penn Pharma has announced plans to invest in additional tablet manufacturing and coating capacity.
Advertisement
Penn Pharma has announced its plans to invest in additional tablet manufacturing and coating capacity to meet customer demand. This investment is in addition to the £14 million ($21.2 million) recently invested in a solid dose contained manufacturing facility to handle potent active pharmaceutical ingredients.
The new £3 million ($4.5 million) investment follows the recent completion of Penn Pharma’s new 15,000-ft2 site for the clinical and commercial manufacture of tablets and capsules.
Penn Pharma has been providing pharmaceutical services for more than 30 years and employs 275 staff on its two sites in South Wales, UK.
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement